Tocagen (NASDAQ:TOCA) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other research firms have also commented on TOCA. Zacks Investment Research lowered Tocagen from a “hold” rating to a “sell” rating in a research report on Thursday, August 16th. Chardan Capital assumed coverage on Tocagen in a research report on Thursday, August 30th. They issued a “buy” rating and a $30.00 price target on the stock. LADENBURG THALM/SH SH assumed coverage on Tocagen in a research report on Wednesday, June 27th. They set a “buy” rating and a $20.00 target price on the stock. HC Wainwright assumed coverage on Tocagen in a research report on Monday, June 11th. They set a “buy” rating and a $14.50 target price on the stock. Finally, B. Riley upped their target price on Tocagen from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $20.75.

NASDAQ TOCA opened at $13.62 on Friday. Tocagen has a 12 month low of $7.52 and a 12 month high of $14.66. The company has a debt-to-equity ratio of 0.56, a current ratio of 6.06 and a quick ratio of 6.06.

Tocagen (NASDAQ:TOCA) last released its quarterly earnings results on Tuesday, August 7th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.25). Tocagen had a negative net margin of 130,944.75% and a negative return on equity of 77.46%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $2.01 million. research analysts anticipate that Tocagen will post -2.69 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in the stock. Granahan Investment Management Inc. MA boosted its position in shares of Tocagen by 16.0% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 42,438 shares of the company’s stock valued at $396,000 after purchasing an additional 5,839 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Tocagen during the 1st quarter valued at about $178,000. Raymond James & Associates bought a new stake in shares of Tocagen during the 2nd quarter valued at about $142,000. First Republic Investment Management Inc. bought a new stake in shares of Tocagen during the 2nd quarter valued at about $170,000. Finally, Millennium Management LLC bought a new stake in shares of Tocagen during the 1st quarter valued at about $402,000. Institutional investors own 28.12% of the company’s stock.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Featured Article: Earnings Per Share

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.